BR9710156A - Composto composições para tratar uma doença cardiovascular assinalada por hipertens o ou isquemia de miocárdio para melhorar lesão isquêmica ou reduzir tamanho de infarto do miocárdio e para reduzir ou níveis de lipídeo os níveis de trigricerídeo ou os níveis de colesterol em um mamífero processos para tratar um paciente sofrendo de hipertensão para tratar um paciente sofrendo de isquemia do miocárdio e para tratar um paciente sofrendo de hiperlipidemia ou de hipercolesterolemia - Google Patents

Composto composições para tratar uma doença cardiovascular assinalada por hipertens o ou isquemia de miocárdio para melhorar lesão isquêmica ou reduzir tamanho de infarto do miocárdio e para reduzir ou níveis de lipídeo os níveis de trigricerídeo ou os níveis de colesterol em um mamífero processos para tratar um paciente sofrendo de hipertensão para tratar um paciente sofrendo de isquemia do miocárdio e para tratar um paciente sofrendo de hiperlipidemia ou de hipercolesterolemia

Info

Publication number
BR9710156A
BR9710156A BR9710156A BR9710156A BR9710156A BR 9710156 A BR9710156 A BR 9710156A BR 9710156 A BR9710156 A BR 9710156A BR 9710156 A BR9710156 A BR 9710156A BR 9710156 A BR9710156 A BR 9710156A
Authority
BR
Brazil
Prior art keywords
treat
patient suffering
hypertension
reduce
levels
Prior art date
Application number
BR9710156A
Other languages
English (en)
Inventor
Michael R Myers
Martin P Maguire
Alfred P Spada
William R Ewing
Henry W Pauls
Yong-Mi Choi-Sledeski
Original Assignee
Rhone Poulenc Rorer Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Pharma filed Critical Rhone Poulenc Rorer Pharma
Publication of BR9710156A publication Critical patent/BR9710156A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32Nitrogen atom
    • C07D473/34Nitrogen atom attached in position 6, e.g. adenine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
BR9710156A 1996-07-08 1997-07-01 Composto composições para tratar uma doença cardiovascular assinalada por hipertens o ou isquemia de miocárdio para melhorar lesão isquêmica ou reduzir tamanho de infarto do miocárdio e para reduzir ou níveis de lipídeo os níveis de trigricerídeo ou os níveis de colesterol em um mamífero processos para tratar um paciente sofrendo de hipertensão para tratar um paciente sofrendo de isquemia do miocárdio e para tratar um paciente sofrendo de hiperlipidemia ou de hipercolesterolemia BR9710156A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2136696P 1996-07-08 1996-07-08
PCT/US1997/011320 WO1998001426A1 (en) 1996-07-08 1997-07-01 Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties

Publications (1)

Publication Number Publication Date
BR9710156A true BR9710156A (pt) 1999-08-10

Family

ID=21803790

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9710156A BR9710156A (pt) 1996-07-08 1997-07-01 Composto composições para tratar uma doença cardiovascular assinalada por hipertens o ou isquemia de miocárdio para melhorar lesão isquêmica ou reduzir tamanho de infarto do miocárdio e para reduzir ou níveis de lipídeo os níveis de trigricerídeo ou os níveis de colesterol em um mamífero processos para tratar um paciente sofrendo de hipertensão para tratar um paciente sofrendo de isquemia do miocárdio e para tratar um paciente sofrendo de hiperlipidemia ou de hipercolesterolemia

Country Status (22)

Country Link
EP (1) EP0912520B1 (pt)
JP (1) JP4202421B2 (pt)
KR (1) KR20000023635A (pt)
CN (1) CN1228770A (pt)
AP (1) AP903A (pt)
AT (1) ATE239725T1 (pt)
AU (1) AU746590B2 (pt)
BG (1) BG103135A (pt)
BR (1) BR9710156A (pt)
CA (1) CA2259538C (pt)
CZ (1) CZ291785B6 (pt)
DE (1) DE69721776T2 (pt)
EA (1) EA001801B1 (pt)
ES (1) ES2199365T3 (pt)
HU (1) HUP9903815A3 (pt)
IL (1) IL127890A0 (pt)
NO (1) NO313671B1 (pt)
OA (1) OA10953A (pt)
PL (1) PL331036A1 (pt)
SK (1) SK2299A3 (pt)
UA (1) UA51716C2 (pt)
WO (1) WO1998001426A1 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6376472B1 (en) * 1996-07-08 2002-04-23 Aventis Pharmaceuticals, Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
GB9723590D0 (en) 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
YU44900A (sh) 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
CN1313861A (zh) 1998-06-23 2001-09-19 葛兰素集团有限公司 2-(嘌呤-9-基)-四氢呋喃-3,4-二醇衍生物
GB9813554D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
AU1186300A (en) 1998-11-25 2000-06-13 Daiichi Radioisotope Laboratories, Ltd. Drugs and reagents containing n-acyloxylated cycloalkyl compounds as the active ingredient
SI1140933T1 (en) * 1998-12-31 2005-02-28 Aventis Pharmaceuticals Inc. Process for preparing n6-substituted deaza-adenosine derivatives
GB0106867D0 (en) * 2001-03-20 2001-05-09 Glaxo Group Ltd Process
CA2446605A1 (en) * 2001-05-10 2002-11-21 Aventis Pharma Deutschland Gmbh Novel processes for the preparation of adenosine compounds and intermediates thereto
EP1258247A1 (en) * 2001-05-14 2002-11-20 Aventis Pharma Deutschland GmbH Adenosine analogues for the treatment of insulin resistance syndrome and diabetes
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
HUP0200849A2 (hu) * 2002-03-06 2004-08-30 Sanofi-Synthelabo N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
EP1375508A1 (en) * 2002-06-27 2004-01-02 Aventis Pharma Deutschland GmbH N6-substituted adenosine analogues and their use as pharmaceutical agents
US7163937B2 (en) 2003-08-21 2007-01-16 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
FR2862969A1 (fr) * 2003-11-28 2005-06-03 Oreal Procede de preparation de derives paraphenylenediamine a groupement pyrrolidinyle, substitue par un radical azote, et composes intermediaires
EP1574508A1 (de) 2004-01-30 2005-09-14 Lonza AG Verfahren zur Herstellung von Acetalen und Ketalen von 3-Amino-5-(hydroxymethyl)-cyclopentan-1,2-diolen, sowie deren Derivaten und Salzen
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
JP2006022045A (ja) * 2004-07-08 2006-01-26 Kaneka Corp 光学活性1−t−ブトキシカルボニル−3−アミノピロリジン塩の単離精製方法
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
US7629351B2 (en) 2006-07-28 2009-12-08 Bristol-Myers Squibb Company N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-2-oxo-3-(6-(trifluoromethyl)quinazolin-4-ylamino) pyrrolidin-1-yl)cyclohexyl)acetamide and other modulators of chemokine receptor activity, crystalline forms and process
US7687508B2 (en) 2006-07-28 2010-03-30 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
US7671062B2 (en) 2006-07-28 2010-03-02 Bristol-Myers Squibb Company Modulators of chemokine receptor activity, crystalline forms and process
DE102007002260A1 (de) 2007-01-16 2008-07-31 Sanofi-Aventis Verwendung von substituierten Pyranonsäurederivaten zur Herstellung von Medikamenten zur Behandlung des Metabolischen Syndroms
US8383812B2 (en) 2009-10-13 2013-02-26 Bristol-Myers Squibb Company N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes
BR112018014525A2 (pt) * 2016-01-14 2018-12-11 Handok Inc compostos que antagonizam receptor de adenosina a3, método para preparação dos mesmos e aplicação médica dos mesmos
CN110627765B (zh) * 2019-10-14 2021-08-20 浙江乐普药业股份有限公司 一种替卡格雷关键中间体的制备方法
CN112047919B (zh) * 2020-09-16 2021-06-18 常州制药厂有限公司 一种替卡格雷中间体及其制备方法
KR102308854B1 (ko) * 2021-02-26 2021-10-05 퓨쳐메디신 주식회사 카보사이클릭 뉴클레오사이드 유도체를 포함하는 코로나바이러스감염증-19 예방 및 치료용 약학적 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5561134A (en) * 1990-09-25 1996-10-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
ES2095960T3 (es) * 1990-09-25 1997-03-01 Rhone Poulenc Rorer Int Compuestos que tienen propiedades antihipertensivas y antiisquemicas.
WO1995018817A1 (fr) * 1994-01-07 1995-07-13 Laboratoires Upsa Nouveaux derives de l'adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant
US5554746A (en) * 1994-05-16 1996-09-10 Isis Pharmaceuticals, Inc. Lactam nucleic acids

Also Published As

Publication number Publication date
IL127890A0 (en) 1999-10-28
AU3645497A (en) 1998-02-02
ES2199365T3 (es) 2004-02-16
EP0912520A4 (en) 1999-10-06
HUP9903815A1 (hu) 2001-04-28
EA199900092A1 (ru) 1999-08-26
PL331036A1 (en) 1999-06-21
JP4202421B2 (ja) 2008-12-24
CZ2499A3 (cs) 1999-05-12
DE69721776T2 (de) 2004-03-25
AU746590B2 (en) 2002-05-02
BG103135A (bg) 1999-11-30
CN1228770A (zh) 1999-09-15
CA2259538A1 (en) 1998-01-15
CA2259538C (en) 2006-12-19
JP2000514801A (ja) 2000-11-07
WO1998001426A1 (en) 1998-01-15
HUP9903815A3 (en) 2002-04-29
EP0912520A1 (en) 1999-05-06
AP9801426A0 (en) 1998-12-31
NO990063L (no) 1999-03-08
NO990063D0 (no) 1999-01-07
OA10953A (en) 2001-10-26
EP0912520B1 (en) 2003-05-07
EA001801B1 (ru) 2001-08-27
SK2299A3 (en) 2000-10-09
DE69721776D1 (de) 2003-06-12
KR20000023635A (ko) 2000-04-25
AP903A (en) 2000-11-24
UA51716C2 (uk) 2002-12-16
ATE239725T1 (de) 2003-05-15
CZ291785B6 (cs) 2003-05-14
NO313671B1 (no) 2002-11-11

Similar Documents

Publication Publication Date Title
BR9710156A (pt) Composto composições para tratar uma doença cardiovascular assinalada por hipertens o ou isquemia de miocárdio para melhorar lesão isquêmica ou reduzir tamanho de infarto do miocárdio e para reduzir ou níveis de lipídeo os níveis de trigricerídeo ou os níveis de colesterol em um mamífero processos para tratar um paciente sofrendo de hipertensão para tratar um paciente sofrendo de isquemia do miocárdio e para tratar um paciente sofrendo de hiperlipidemia ou de hipercolesterolemia
BR9507327A (pt) Composto composições para tratar uma donça cardiovascular marcada por hipertensão ou hipertensão ou isquemia do miocárdio melhorar os danos isquémicos ou reduzir o tamanho do infarto do miocárdio e reduzir niveis de lipideos triglicerideos ou de colesterol em um mamifero e processos para tratar um paciente que sofre de hipertensão de isquemia do miocárdio e de hiperlipidemia ou hipercolesterolina para melhorar em um paciente danos isquémicos ou o tamanho do infarto do miocádio e para preparar um derivado substancialmente opticamente puro de 2 substituido-2-amido-1-(heteroar-2-3-il) etano
AR012269A1 (es) COMPOSICIoN FARMACÉUTICA Y USO DE LA MISMA PARA LA FABRICACIoN DE MEDICAMENTOS
FR16C0008I2 (fr) Utilisation combinee de valsartane et bloqueurs du canal de calcium a but therapeutique
PT1023891E (pt) Composicao anidra de descoloracao das fibras queratinicas compreendendo a associacao de polimeros anfifilicos anionicos e/ou nao ionicos compreendendo pelo menos uma cadeia gorda e de polimeros substantivos cationicos ou anfotericos
BR9908690A (pt) Composição farmacêutica contendo estatina e aspirina
EE04390B1 (et) Paikne preparaat dermatoloogiliste seisundite raviks
MA26536A1 (fr) Association de compositions pharmaceutiques d'atorvastatine et d'agents antihypertensifs, et procede pour leur preparation.
TNSN00110A1 (fr) Sel mutuel d'amlodipine et d'atorvastatine, procede pour sa preparation et compositions pharmaceutiques le contenant
BR9705926A (pt) Composição tópica utilização e processo para limitar diminuir e/ou impedir a transfêrencia de uma composição
CY2010002I2 (el) Στepεη φαρμακευτικη συνθεση πepιεχοντας παραγωγα βενζοφουρανιου
TNSN98158A1 (fr) Associations pharmaceutiques d'amlodipine et d'une statine, et procede pour leur preparation
BR0011006A (pt) Prõ-drogas mútuas de amlodipina e atorvastatina
DK0710315T3 (da) Forskallingsplade med drager med omtrentligt U-formet tværsnit
NO983526D0 (no) Dihydrobenzofuran og relaterte forbindelser anvendelig som anti-inflammatoriske midler
UA25166A (uk) Спосіб хірургічhого ослаблеhhя дії верхhього косого м'яза по в.і. ємчеhку
BR1100553A (pt) Kit para o diagnóstico imunológico da doença de chagas usando antìgenos recombinantes conjugados a uma atividade enzimática
BR9501120A (pt) Alavanca para levantamento de dormentes para ajustar o posicionamento dos mesmos para a colocaçao de grampos deenik
ECSP003493A (es) Profarmacos mutuos de amlodipino y atorvastatina
KR970051782U (ko) 엘리베이터 편심 보정장치
KR970044918U (ko) 불평형 모멘트를 보상하는 평형기

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved
B25D Requested change of name of applicant approved
B25G Requested change of headquarter approved
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1891 DE 03/04/2007.